Pre-implantation basiliximab reduces incidence of early acute rejection in pediatric heart transplantation.
J Heart Lung Transplant
1279 - 1284.
Basiliximab is an anti-CD25 monoclonal antibody used as induction therapy in solid-organ transplantation. In this study we aim to determine whether pre-operative administration of basiliximab is beneficial in preventing early heart allograft rejection.
|Title:||Pre-implantation basiliximab reduces incidence of early acute rejection in pediatric heart transplantation.|
|Keywords:||Acute Disease, Antibodies, Monoclonal, Biopsy, Child, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Graft Rejection, Great Britain, Heart Transplantation, Humans, Immunosuppressive Agents, Incidence, Interleukin-2 Receptor alpha Subunit, Lymphocyte Count, Male, Preoperative Care, Prognosis, Recombinant Fusion Proteins, Retrospective Studies, Survival Rate, T-Lymphocytes, Time Factors, Transplantation, Homologous|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Child Health|
Archive Staff Only